Chlorambucil carcinogenesis in BALB/c mice.
Chlorambucil, a drug used in the treatment of neoplastic and non-neoplastic disease, was administered by gavage to BALB/c mice at a dose of 1.0 mg/kg body wt. 5 times per week for 12 weeks to test its carcinogenicity. The survival was statistically reduced in treated animals of both sexes (P less than 0.001). The treatment induced a significant increase in lung tumours (males, P less than 0.001; females, P less than 0.001) and lymphoreticular system tumours (males P less than 0.01; females, P less than 0.001) in both sexes and mammary carcinomas in female mice (P less than 0.05). These results with other investigations reported in literature, suggest that chlorambucil is carcinogenic in laboratory animals, mutagenic and that it could be a potential carcinogenic hazard to man.
Cavaliere
A
A
Institute of Pathological Anatomy and Histology, Perugia University, Italy.
Pietropaoli
N
N
Alberti
P F
PF
Vitali
R
R
D000230:Adenocarcinoma / Q000139:chemically induced / Q000453:epidemiology; D000284:Administration, Oral; D000818:Animals; D002699:Chlorambucil / Q000008:administration & dosage / Q000633:toxicity*; D005260:Female; D015994:Incidence; D007951:Leukemia, Myeloid / Q000139:chemically induced / Q000453:epidemiology; D008175:Lung Neoplasms / Q000139:chemically induced / Q000453:epidemiology; D008224:Lymphoma, Follicular / Q000139:chemically induced / Q000453:epidemiology; D008297:Male; D008325:Mammary Neoplasms, Experimental / Q000139:chemically induced / Q000453:epidemiology; D051379:Mice; D008807:Mice, Inbred BALB C; D009374:Neoplasms, Experimental / Q000139:chemically induced* / Q000453:epidemiology
D002699:Chlorambucil